Waksman

S. A. Waksman, The Mntibiotic Era, The Waksman Eoundation of Japan, Inc., University of Tokyo Press, Tokyo, Japan, 1975, Chapt. 1 and 2. 

S. A. Waksman, ed., Mctinomjdn Nature, Formation, andMctivities, Wiley-Interscience, New York, 1968. 

U. HoUstein, Chem. Rev. 74, 625 (1974) "Sebnan A. Waksman Conference on Actinomycins Their Potential for Cancer Chemotherapy," Cancer Chemother. Rept. 58 (1974). 

Figure 13.26 Schematic diagram of the SH2 domain from the Src tyrosine kinase with bound peptide. The SH2 domain (blue) comprises a central p sheet surrounded by two a helices. Three positively charged residues (green) are involved in binding the phosphotyrosine moiety of the bound peptide (red). (Adapted from G. Waksman et al.. Cell 72 779-790, 1993.)...

Waksman, G., et al. Binding of a high affinity phosphoty-rosyl peptide to the Src SH2 domain crystal structures of the complexed and peptide-free forms. Cell 72 779-790, 1993. 

Waksman, S.A. and Lechevalier, H.A. U.S. Patent 2,992,162 July 11,1961 assigned to Rutgers Research and Educational Foundation... 

Waksman, S.A. and Schatz, A. U.S. Patent 2,449,866 September 21, 1948 assigned to Rutgers Research and Endowment Foundation Bartels, C.R., Bryan, W.L. and Berk, B. U.S. Patent 2,868,779 January 13, 1959 assigned to Olin Mathieson Chemical Corporation... 

Farazi TA, Waksman G, Gordon JT (2001) The biology and enzymology of protein N-myristoylation. J Biol Chem 276 39501-39504... 

Waksman Collection, Institute of Microbiology, Rutgers University, New Brunswick, N.J./USA... 

Stiepton dn was isolated by Waksman in 1944, and its activity against M tuberculosis ensured its use as a primaiy ding in the treatment of tuberculosis. Unfortunately, its ototoxicity and the rapid development of resistance have tended to modify its usefulness, and although it still remains a front-hne dmg against tuberculosis it is usually used in combination with isoniazid and p(4)-aminosalicyhc acid (section 11.5). Streptomycin also shows activity against other types of bacteria,... 

Waksman G, Kominos D, Robertson SR, Pant N, Baltimore D, Birge RB, Cowbum D, Hanafusa H, Mayer BJ, Overduin M, Resh MD, Rios CB, Silverman L, Kuriyan J. Crystal structure of the phophotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature 1992 358 646-653. 

Waksman Y, Olson SM, Carlisle SJ, Cabral, GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 1999 288 1357-1366. 

Commercial neomycin is a complex mixture of aminoglycoside antibiotics originally isolated from a culture of Stn.tptomyc.zi, ( n.adiaz by Waksman and his co-workers in 1949. The principle components of the mixture are neomycin B(I) and neomycin C(II) together with a small quantity of neaminel, a degradation product of neomycin formerly known as neomycin A. Table 1 shows the content variability of neomycin B and C and neamine in commercial samples of neomycin as reported in the literature. Neomycins LP-A, LP-B and LP-C which chemically are the mono N-acetyl derivatives of neomycins A, B and C may also be present in small amounts. Several other minor components have recently been identified as paromamine, paromomycin I and paromomycin II. (Also known as neomycins D, E and F respectively). 

Waksman et al, in 1949, first reported the production of neomycin by fermentation of a culture of S. faUcid-Lcut. (3535). The same organism subsequently formed the basis of an industrial fermentation process for the biosynthesis of neomycin287,288. isolation of the antibiotic from the fermentation media is accomplished by use of ion-exchange resins, such as Amberlite IRC 50 25,250,251. 

Following the original report by Waksman, a number of other authors have described S. fi- iad Lae to yield antibiotics on fermentation. 

---